We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

28 hedge funds and large institutions have $10.9M invested in Moleculin Biotech in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

23% more capital invested

Capital invested by funds: $8.88M → $10.9M (+$2.05M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

4% more funds holding

Funds holding: 27 → 28 (+1)

0.01% more ownership

Funds ownership: 0.02% → 0.03% (+0.01%)

Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
6
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.11M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$229K
3
State Street
State Street
Massachusetts
+$218K
4
SCM
Sio Capital Management
New York
+$153K
5
BlackRock
BlackRock
New York
+$138K

Top Sellers

Rank Fund Capital Flow
1
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$136K
2
Squarepoint
Squarepoint
New York
-$118K
3
TSS
Two Sigma Securities
New York
-$111K
4
CSS
Cubist Systematic Strategies
Connecticut
-$109K
5
Charles Schwab
Charles Schwab
California
-$50K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.84M +$2.11M +1,544 +124%
SCM
2
Sio Capital Management
New York
$3.69M +$153K +112 +4%
BlackRock
3
BlackRock
New York
$1.02M +$138K +101 +16%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$871K +$229K +168 +36%
State Street
5
State Street
Massachusetts
$220K +$218K +160 New
Northern Trust
6
Northern Trust
Illinois
$186K – – –
Citadel Advisors
7
Citadel Advisors
Florida
$140K +$87.3K +64 +173%
XT
8
XTX Topco
Cayman Islands
$121K +$120K +88 New
SFI
9
Susquehanna Fundamental Investments
Pennsylvania
$115K -$1.36K -1 -1%
GCP
10
GSA Capital Partners
United Kingdom
$114K +$113K +83 New
Truist Financial
11
Truist Financial
North Carolina
$107K – – –
OQS
12
Occudo Quantitative Strategies
Florida
$107K +$25.9K +19 +32%
Goldman Sachs
13
Goldman Sachs
New York
$94K +$94.2K +69 New
VF
14
Virtu Financial
New York
$93K +$91.4K +67 New
WIC
15
Whitegate Investment Counselors
New Hampshire
$62K – – –
RJA
16
Raymond James & Associates
Florida
$55K – – –
Morgan Stanley
17
Morgan Stanley
New York
$36K – – –
Bank of America
18
Bank of America
North Carolina
$24K – – –
Rockefeller Capital Management
19
Rockefeller Capital Management
New York
$10K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$9K +$9.55K +7 New
UBS Group
21
UBS Group
Switzerland
$4K +$4.09K +3 New
Osaic Holdings
22
Osaic Holdings
Arizona
$3K – – –
CFO
23
CVA Family Office
Colorado
$2K – – –
APA
24
American Portfolios Advisors
New York
$1.23K – – –
CAPTRUST Financial Advisors
25
CAPTRUST Financial Advisors
North Carolina
$1K – – –
1
2

MBRX Hedge Fund Activity: Q2 2021 in Review

28 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2021, worth a combined $10.9M — up 23% from $8.88M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MBRX positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.11M. The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $136K sold.

  • 28 institutional investors held Moleculin Biotech (MBRX) as of Q2 2021, up from 27 in Q1 2021.
  • Funds reported $10.9M of Moleculin Biotech stock for Q2 2021, up 23% quarter-over-quarter.
  • 7 funds opened new Moleculin Biotech positions in Q2 2021 and 6 closed out, a net change of +1 holder.
  • The largest Moleculin Biotech buyer in Q2 2021 was Vanguard Group, an estimated $2.11M added.
  • The largest Moleculin Biotech seller in Q2 2021 was Harel Insurance Investments & Financial Services, an estimated $136K sold.

Based on aggregated 13F filings for Q2 2021.